A collaborative study published today in the journal Cell Reports provides evidence for a new molecular cause for neurodegeneration in Alzheimer’s disease. The study, led by researchers at Baylor ...
– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, ...
Technological and computational advances in recent years, from cryo-electron microscopy to sequencing technologies and machine learning, have substantially deepened our understanding of RNA splicing, ...
A wide spectrum of cancer-associated genetic alterations, including those that result in changes to the splicing of pre–messenger RNA (mRNA), can lead to the presentation of aberrant peptides as ...
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...
PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro. PepGen on Wednesday ...
Scientists have created a model to study the role of RNA splicing defects in Alzheimer's disease, revealing degeneration and toxicity caused by neuron hyperexcitability. Researchers have puzzled over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback